Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.
CAMP4 Therapeutics Corp (NASDAQ: CAMP) delivers pioneering RNA-based therapies targeting genetic diseases through its innovative RAP Platform™. This page provides investors and researchers with verified updates on clinical developments, strategic partnerships, and regulatory milestones.
Access real-time announcements about CAMP4's progress in upregulating gene expression for CNS and liver disorders. Track key updates including clinical trial phases, FDA designations, and collaborative research initiatives with industry leaders like BioMarin.
All content undergoes rigorous verification to ensure compliance with financial reporting standards. Bookmark this page for centralized access to earnings reports, therapy pipeline advancements, and scientific publications related to regRNA modulation technologies.
CAMP4 Therapeutics (NASDAQ: CAMP) reported its full year 2024 financial results and provided updates on its clinical programs. The company's Phase 1 trial of CMP-CPS-001 for Urea Cycle Disorders (UCDs) is progressing, with two of four multiple ascending dose cohorts completed. Safety data is expected in Q4 2025.
Key financial highlights include:
- R&D expenses: $38.8 million (down from $40.6 million in 2023)
- G&A expenses: $14.9 million (up from $11.6 million in 2023)
- Net loss: $51.8 million (compared to $49.3 million in 2023)
- Cash position: $64.0 million (sufficient until Q2 2026)
The company nominated development candidate CMP-SYNGAP-01 for SYNGAP1-related disorders and plans to initiate GLP toxicology studies in 2025. CAMP4 also expects to begin a Phase 1b trial in female OTC heterozygotes in Q2 2025.
CAMP4 Therapeutics (NASDAQ: CAMP) has strengthened its Board of Directors with the appointments of two industry veterans: Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP. The company, focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies, aims to enhance its strategic guidance for multiple drug development programs.
Dr. Williams brings over 30 years of biopharma experience, having contributed to notable drugs like LEUKINE®, ENBREL®, and SPINRAZA®. His previous roles include President of R&D at Sana Biotechnology, EVP of R&D at Biogen, and CEO of ZymoGenetics.
Dr. Stewart, formerly Chief Medical Officer at Rhythm Pharmaceuticals and GlaxoSmithKline, has extensive clinical development experience across all trial phases and has been instrumental in launching therapies including AVANDIA® and TANZEUM®. The appointments will support CAMP4's advancement of its lead clinical program for urea cycle disorders and preclinical program for SYNGAP1-related disorders.
CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotechnology company focused on regRNA-targeting antisense oligonucleotide therapies, has announced its participation in three major upcoming investor conferences.
The company's President & CEO, Josh Mandel-Brehm, will present at:
- Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Virtual corporate presentation on February 12, 2025, at 10:00 a.m. EST
- Leerink Partners Global Healthcare Conference - Fireside chat in Miami, Florida on March 10, 2025, at 4:20 p.m. EST
- Barclays 27th Annual Global Healthcare Conference - One-on-one meetings in Miami, Florida on March 11-12, 2025
The presentations will be webcast live on CAMP4's investor relations website, with replays available for 30 days after the events.
CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotech company specializing in regRNA-targeting antisense oligonucleotide (ASO) therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President & CEO, Josh Mandel-Brehm, will deliver a corporate update presentation on Wednesday, January 15, 2025, at 3:45 p.m. PST in San Francisco, California.
The presentation will be available through a live webcast on CAMP4's investor relations website. Interested parties can access the webcast at www.investors.camp4tx.com, and a replay will remain available on the company's website for 30 days after the conference.
CAMP4 Therapeutics provided corporate updates and key objectives for 2025, highlighting significant progress in their clinical programs. The company completed its IPO, raising gross proceeds of $82.1 million. Their lead program, CMP-CPS-001 for urea cycle disorders (UCDs), demonstrated favorable safety results in the Single Ascending Dose (SAD) portion of Phase 1 study, with all treatment emergent adverse events being mild or moderate.
The company has completed dosing in the first two Multiple Ascending Dose (MAD) cohorts and initiated Cohort 3. The FDA granted both Rare Pediatric Disease Designation and Orphan Drug Designation to CMP-CPS-001. CAMP4 also entered a strategic research collaboration with BioMarin and was added to the Russell 2000® Index. Key upcoming milestones include MAD safety and biomarker data expected in 2H 2025, and the initiation of a new discovery program targeting GBA1 regRNA for Parkinson's disease treatment.
CAMP4 Therapeutics has appointed John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors. Both bring extensive experience in RNA-based medicines to the company.
Dr. Maraganore, former CEO of Alnylam, led the development and commercialization of the first four RNAi therapeutics. He also has a background in oncology, cardiovascular, inflammatory, and metabolic diseases from his time at Millennium Pharmaceuticals.
Dr. Meyers, with over two decades in life sciences, was Senior VP of Research at Alnylam and is currently on several scientific advisory boards. She has significant expertise in developing RNA-based therapies and has held leadership roles in various biotech firms.
CEO Josh Mandel-Brehm expressed excitement about leveraging their expertise to advance CAMP4's RNA Actuating platform, aiming to upregulate gene expression to treat genetic diseases. Both advisors see potential for CAMP4 to impact a broad range of diseases through innovative RNA medicines.
CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotechnology company, announced its participation in the Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace Hotel, NYC, from December 3-5, 2024. CAMP4's management will present on December 5, 2024, from 1:00-1:25 PM ET.
The presentation will be available via a live webcast on the company's investor relations website. For meeting requests or more details, contact your institutional representative or email the company.
CAMP4 Therapeutics reported Q3 2024 financial results and corporate updates. The company completed an IPO raising $82.1M in gross proceeds. Key highlights include completing the Single Ascending Dose portion of Phase 1 study for CMP-CPS-001, with safety data expected in Q1 2025, and entering a strategic collaboration with BioMarin valued at over $370M. The company reported a net loss of $13.5M for Q3 2024, with R&D expenses at $9.7M and G&A expenses at $3.8M. Cash position was $2.5M at quarter-end, strengthened by the IPO proceeds.
CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotechnology company, has announced the pricing of its initial public offering (IPO). The company is offering 6,820,000 shares of common stock at $11.00 per share, aiming to raise approximately $75.0 million in gross proceeds. Trading of CAMP4's common stock on the Nasdaq Global Market is expected to begin on October 11, 2024, under the ticker symbol 'CAMP'.
The offering is set to close on October 15, 2024, subject to customary conditions. CAMP4 has also granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares at the IPO price. J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair are acting as joint book-running managers for the offering.
CalAmp (Nasdaq: CAMP) has announced a Restructuring Support Agreement (RSA) with Lynrock Lake Master Fund LP, its principal secured lender, to significantly reduce debt and take the company private. Lynrock will exchange approximately $229 million of Convertible Senior Secured Notes into equity interests, becoming the principal equity owner. Despite the Chapter 11 filing, operations will continue without disruption. This move aims to enhance financial flexibility, allowing CalAmp to invest in innovation and support evolving customer needs. The restructuring plan is expected to navigate swiftly with court approval, reinforcing CalAmp's financial health and operational capabilities.
